OyaGen, Inc has a discovery stage hit-to-lead oncology program for the identification and development of treatments that will reduce cancer progression. Cellular proteins known as AID, APOBEC3A, APOBEC3B are gene editing enzymes that become misregulated in various cancers to cause chromosomal mutations that drive the development and progression in several types cancer.
OyaGen’s CEO is a founder and thought leader on APOBEC RNA and DNA editing enzymes and has contributed over 120 peer-review scientific papers in the past 30 years
OyaGen is recognized nationally and internationally for its platform of drug discovery methods and reagents on the APOBEC enzymes using support in grants from NIH, The Bill and Melinda Gates foundation and equity investment
Drugs that inhibit APOBEC enzymes will address unmet needs in mitigating cancer risk and cancer progression that are characteristic of B cell lymphoma and leukemia, breast cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma, stomach cancer, metastatic disease, non-small cell lung cancer and ovarian cancer.
Disease progress in a variety of cancers is widely recognized as driven by unregulated and off-target mutagenic activity by APOBEC enzymes on chromosomal DNA and yet this fundamental cancer mechanism remains an unmet need in drug discovery.
OyaGen’s unique high throughput assay for inhibitors of AID gene editing activity has been third part validated in identifying compounds that are selective inhibitors of the pathway AID uses to enter the cell nucleus and access chromosomal DNA.
Other high throughput assays that seek inhibitors APOBEC3A and APOBEC3B gene mutation activity are in concept and development stages OyaGen has a platform of cell and molecular methods that will enable and validate hits from its oncology drug discovery campaign and accelerate hit-to-lead optimization and IND-enabling studies.
OyaGen is uniquely positioned to deliver high impact in novel cancer therapeutics. The company seeks to partner or license Oya1 or obtain a tranched capital raise enabling OyaGen to fully develop and pursue novel cancer treatments that are anticipated to prevent tumor progress, reduce cancer risk and save lives. Pre-IND discussions with the FDA are anticipated in 2022 assuming sufficient funding.
Innovative new cancer therapies are in high demand
OyaGen’s therapeutics currently have no competition